Prediction of Chronic Kidney Disease Following Pre-eclampsia: Diagnosis and Early Care

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05056701

Acronym

PRECEDE

Enrollment

400

Registered

2021-09-24

Start date

2022-05-30

Completion date

2037-05-30

Last updated

2024-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Keywords

chronic kidney disease (CKD), preeclampsia

Brief summary

Pre-eclampsia (PE) is a pregnancy-associated syndrome of variable severity, classically defined by the combination of hypertension and proteinuria in a previously non-hypertensive or proteinuric patient. These symptoms normally resolve within 2-3 months after delivery regardless of the severity of the pre-eclampsia. Regardless of its definition, preeclampsia is associated with an increased risk of obstetric events and, for the mother, an increased risk of developing chronic kidney disease (CKD), hypertension, diabetes and cardiovascular disease in the broad sense. The relationship between preeclampsia and Chronic Kidney Disease is, however, complex and not fully understood. Investigator proposes an interventional study to identify the diagnosis of Chronic Kidney Disease in patients who have developed an episode of Preeclampsia.

Interventions

OTHERannual follow-up during 10 years

an annual follow-up is carried out systematically for a total of 10 years in order to detect the subsequent occurrence of CKD

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Meeting the preeclampsia criteria or one of its complications (eclampsia, HELLP syndrome) according to the ISSHP 2018 definitions within the last 5 years * Having signed the informed consent * Person affiliated to social security

Exclusion criteria

* Patient with mental disability or language barrier preventing understanding of the study or consent * Person deprived of liberty by judicial or administrative decision * Person under forced psychiatric care * Person subject to a legal protection measure

Design outcomes

Primary

Measure	Time frame	Description
prevalence of the Chronic Kidney Disease (CKD)	until 10 years	prevalence of the CKD is measured by the the rate of new CKD Diagnoses (according to the standard definitions)

Countries

France

Contacts

Primary ContactChristelle JADEAU

cjadeau@ch-lemans.fr+33 2 44 71 07 81

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026